Welcome to our dedicated page for Axcelis Tech Ord news (Ticker: ACLS), a resource for investors and traders seeking the latest updates and insights on Axcelis Tech Ord stock.
The Axcelis Technologies Inc (ACLS) news page on Stock Titan aggregates company announcements, industry event participation and regulatory disclosures focused on its role in the semiconductor equipment market. Axcelis describes itself as a leading supplier of enabling ion implantation solutions for the semiconductor industry, with more than 45 years of experience providing high-productivity systems and lifecycle support.
Investors and industry followers can use this page to monitor Axcelis’ updates on product launches, technology platforms and market engagement. Recent news has highlighted the introduction of the Purion Power Series+ ion implant platform for next generation power devices, including silicon carbide (SiC) power devices and superjunction architectures, as well as the GSD Ovation ES high current implanter for engineered substrates. Company releases also cover its participation in major industry events such as SEMICON Japan and the International Conference on Silicon Carbide and Related Materials (ICSCRM), where Axcelis technologists present technical work on SiC and related materials.
The feed also includes financial and corporate developments, such as quarterly results announcements, conference call schedules and Axcelis’ participation in investor conferences. A significant recent development is the all-stock merger agreement with Veeco Instruments Inc., under which Veeco is expected to become a wholly owned subsidiary of Axcelis, subject to regulatory and shareholder approvals.
By following this ACLS news page, readers can track Axcelis’ communications on its ion implantation product portfolio, aftermarket strategy, global customer engagement and planned combination with Veeco, all drawn from official press releases and SEC-referenced materials.
Axcelis Technologies reported a strong financial performance in Q3 2022, with revenue of $229.2 million, up from $221.2 million in Q2. Operating profit decreased slightly to $53.2 million, while net income was $40.3 million, or $1.21 per diluted share, down from $44.2 million or $1.32 per diluted share. Gross margin improved to 45.1%. The company also reported a record systems backlog of $1.1 billion and booking of $337.1 million. For Q4 2022, Axcelis expects revenue of $232-240 million and operating profit of $41-45 million.
Axcelis Technologies (Nasdaq: ACLS) announced shipments of its PurionH™ and PurionXE™ implanters to a major analog chip manufacturer in North America. This follows a series of multi-year purchase orders aimed at enhancing the chipmaker's manufacturing capabilities. CEO Mary Puma highlighted the customer's confidence in Axcelis, reflecting strong business relationships.
The company has over 40 years of experience in the semiconductor sector, focusing on high-productivity solutions and support for critical ion implantation processes.
Axcelis Technologies (Nasdaq: ACLS) will release its third quarter 2022 financial results on November 2, 2022, at 4:00 p.m. ET. A follow-up conference call to discuss the results is scheduled for November 3, 2022, at 8:30 a.m. ET. Interested parties can access the call via an audio webcast on the company's website. The company specializes in high-productivity solutions for the semiconductor industry, particularly in the area of ion implantation systems.
Axcelis Technologies, Inc. (NASDAQ: ACLS) announced the qualification of its Purion XEmax high energy ion implant system for production at a leading CMOS image sensor manufacturer. This advancement is expected to enhance image sensor technology and production capabilities, driving growth in the image sensor market. The Purion XEmax is designed for high-performance applications, featuring advanced filtration systems to maintain photodiode quality. This move reflects Axcelis’ commitment to innovation in semiconductor solutions amid increasing demand.
Axcelis Technologies (NASDAQ: ACLS) announced its sponsorship and participation in the International Conference on Ion Implantation Technology 2022, set for September 25-29 in San Diego, CA. This marks over 40 years of Axcelis's involvement in the conference series. The event will focus on advances in ion implantation technologies, featuring presentations on topics such as the Purion H200™ single wafer implanter and advanced angle control solutions. Axcelis aims to address critical challenges in the semiconductor industry through these discussions.
Axcelis Technologies, based in Beverly, Mass, announced its participation in two upcoming investor conferences. The D.A. Davidson Big Sky Technology Summit will occur on August 22-23, 2022, with one-on-one meetings scheduled for August 23rd. Additionally, Axcelis will attend the Needham Virtual 3rd Annual SemiCap and EDA Conference on August 25, 2022, facilitating one-on-one meetings for interested investors. Axcelis has over 40 years of experience in the semiconductor industry, specializing in ion implantation solutions.
Axcelis Technologies (ACLS) reported robust financial results for Q2 2022, achieving $221.2 million in revenue, a rise from $203.6 million in Q1. The operating profit increased to $54.1 million, with net income at $44.2 million or $1.32 per diluted share. Gross margin improved to 44.8%. The company experienced record system bookings of $432.8 million and backlog reaching $869.5 million. For FY 2022, revenue is projected to exceed $875 million, with a gross margin of approximately 42.5%.
Axcelis Technologies (Nasdaq: ACLS) has officially opened its new Axcelis Asia Operations Center in Pyeongtaek-Si, Korea, significantly increasing its manufacturing capacity. The state-of-the-art facility spans over 44,000 square feet and is certified by ISO 45001 for occupational health and safety. Initial shipments commenced in Q1, and the center aims to enhance customer relationships and streamline operations across Asia. This investment is expected to create numerous local jobs in various functions.
Axcelis Technologies (Nasdaq: ACLS) announced robust financial expectations for Q2 2022, projecting revenues exceeding $215 million, a gross margin of approximately 41%, operating profit around $41 million, and earnings per diluted share of about $1.00. The company cites strong demand for ion implantation solutions within the semiconductor sector, with booking levels supporting over $850 million in total revenue for the year. A conference call is scheduled for August 4, 2022, to discuss these results in further detail.
Axcelis Technologies (Nasdaq: ACLS) has announced significant progress in the power device segment with multiple shipments of its Purion H200 Si 200mm and SiC Power Series™ 150mm high current implanters to major power device chipmakers in Asia. These systems are intended for high-volume production in the automotive sector, which is experiencing rapid growth.
Executive Vice President Bill Bintz stated that the power device segment is projected to comprise 30% to 40% of their system sales in 2022, highlighting the company's commitment to support electric vehicle technology through advanced manufacturing solutions.